Roche Will Buy Obesity And Diabetes Drugmaker Carmot Therapeutics In $2.7 Billion Deal
Roche said Carmot Therapeutics’ research and development portfolio “has great potential to treat obesity, diabetes and potentially other diseases” both on its own and in combination with Roche’s assets.
Roche said Carmot Therapeutics’ research and development portfolio “has great potential to treat obesity, diabetes and potentially other diseases” both on its own and in combination with Roche’s assets.
What's Your Reaction?
